The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for
体温调节和血管舒缩症状的科学:可能的新目标
基本信息
- 批准号:8784849
- 负责人:
- 金额:$ 4.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-08-15 至 2016-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgingAmericanAntidepressive AgentsAreaAwardBasic ScienceCancer SurvivorCardiovascular systemClinicalClinical ResearchCognitiveComplementary and alternative medicineConsensusDataDevelopmentDistrict of ColumbiaDoseEtiologyExerciseExercise PhysiologyFDA approvedFundingGoalsHealthHomeostasisHot flushesJournalsKnowledgeLinkMedicalMedicineMenopausal SymptomMenopauseMeta-AnalysisNational Institute on AgingNeurobiologyNeuropharmacologyNight SweatingNorth AmericaOmega-3 Fatty AcidsOralOutcomeParoxetineParticipantPathway interactionsPharmaceutical PreparationsPhysiologic ThermoregulationPhysiologyProfessional OrganizationsPublicationsPublishingQuality of lifeRandomized Clinical TrialsRecommendationResearchResearch PersonnelResearch PriorityResourcesScienceScientific Advances and AccomplishmentsScientistSecureSelective Serotonin Reuptake InhibitorSeminalSkinSocietiesStagingSymptomsTemperatureTravelUnited States National Institutes of HealthVasomotorWomanWomen&aposs HealthWorkYogabaseclinical efficacycognitive functiondepressive symptomsdrug developmentexperiencehealthy aginghormone therapyinnovationmeetingsmiddle agemultidisciplinaryneuroimagingneurophysiologynew therapeutic targetposterspre-clinical researchprogramspublic health relevancerandomized trialreproductivestandard caresuccesssymposiumweb siteworking group
项目摘要
DESCRIPTION (provided by applicant): More than 80% of women experience vasomotor symptoms (VMS; hot flashes and night sweats) during the menopausal transition. The use of hormone therapy, the standard treatment for VMS, decreased by 75% after publication of the findings from the Women's Health Initiative. The only FDA-approved nonhormonal treatment for VMS is paroxetine, a low-dose antidepressant that showed significant but modest efficacy in randomized trials. In the past decade, our understanding of the efficacy of nonhormonal therapies on VMS has increased considerably based on findings from randomized clinical trials. Unfortunately, the results from these trials show no-to-minimal efficacy, and two nonhormonal VMS medications recently failed to win FDA approval. Women therefore have very few nonhormonal treatment options for VMS. To address the continuing need for development of new nonhormonal therapies for VMS, we propose a multidisciplinary, 2-day conference, The Science of Thermoregulation and Vasomotor Symptoms: Possible New Targets for Treatment. The conference will convene a diverse group of 20 to 25 basic and clinical researchers as well as clinicians to discuss normal and aberrant thermoregulation, the neurophysiology of VMS, and new potential treatment targets. The aim of the conference is to facilitate synthesis and exchange of new data by promoting scientific exchange among experts who do not typically interact scientifically but whose work informs the others. In recent years, scientific understanding of the mechanisms involved in VMS has evolved considerably based on findings from basic science, physiology, neuroimaging, and studies of skin dynamics. The specific aims are to 1) describe current understanding of the physiology and neuropharmacology of thermoregulation and VMS; 2) describe current understanding of nonhormonal treatments for VMS; 3) review existing evidence from studies linking VMS to adverse health outcomes in women, including quality of life, cardiovascular outcomes, and cognitive function; 4) integrate new and emerging data from multiple areas of inquiry into an initial conceptual framework to better understand the causal pathway of VMS and potential avenues for new drug development. The Day 1 public symposium, open to 80 participants, will feature oral and poster presentations of recent scientific advances in thermoregulation and VMS and discussion of the implications of this new evidence for the development of nonhormonal VMS treatments. On Day 2, facilitated working groups will discuss and respond to targeted questions regarding research priorities. We offer four travel awards for new investigators. The meeting will be sponsored by The North American Menopause Society (NAMS) and will take place October 14-15, 2014, just before the 25th NAMS Annual Meeting in Washington, DC. The symposium recommendations will be presented in a special session at the NAMS meeting. A Program Planning Committee will prepare a conference summary for oral presentation at the NAMS Annual Meeting, an executive summary of the recommendations for publication in the official NAMS journal, Menopause, and a lay version to be published on the NAMS website.
描述(申请人提供):超过80%的女性在更年期过渡期间出现血管舒缩症状(VMS;潮热和盗汗)。在妇女健康倡议的研究结果公布后,激素疗法的使用减少了75%,这是VMS的标准治疗方法。FDA批准的唯一治疗VMS的非激素疗法是帕罗西汀,这是一种低剂量的抗抑郁药,在随机试验中显示出显著但不大的疗效。在过去的十年中,基于随机临床试验的结果,我们对非激素疗法治疗VMS的疗效的了解有了很大的提高。不幸的是,这些试验的结果显示没有或只有很小的疗效,最近两种非激素VMS药物未能获得FDA的批准。因此,女性对于VMS的非激素治疗选择很少。为了应对VMS新的非激素疗法的持续开发需求,我们建议召开一个为期两天的多学科会议,名为体温调节和血管运动症状的科学:可能的新治疗靶点。会议将召集由20至25名基础和临床研究人员以及临床医生组成的不同小组,讨论正常和异常体温调节、VMS的神经生理学以及新的潜在治疗目标。会议的目的是通过促进专家之间的科学交流,促进新数据的合成和交流,这些专家通常不进行科学互动,但其工作为其他专家提供信息。近年来,在基础科学、生理学、神经成像和皮肤动力学研究的基础上,对VMS涉及的机制的科学理解有了很大的发展。具体目标是1)描述体温调节和VMS的生理学和神经药理学的当前了解;2)描述VMS的非激素治疗的当前理解;3)综述VMS与女性不良健康结局(包括生活质量、心血管结果和认知功能)之间的研究的现有证据;4)将来自多个调查领域的新的和新兴的数据整合到一个初步的概念框架中,以更好地了解VMS的致病途径和新药开发的潜在途径。第一天的公开研讨会向80名与会者开放,将以口头和海报形式介绍体温调节和VMS方面的最新科学进展,并讨论这一新证据对开发非激素VMS治疗的影响。在第二天,促进工作组将讨论并回答有关研究优先事项的有针对性的问题。我们为新调查人员提供四个旅行奖励。这次会议将由北美更年期协会(NAMS)赞助,将于2014年10月14日至15日在华盛顿举行第25届NAMS年会之前举行。专题讨论会的建议将在不结盟运动会议的特别会议上提出。方案规划委员会将准备一份会议摘要,供在全国妇女协会年会上口头陈述,一份建议的执行摘要,供在全国妇女协会官方期刊《更年期》上发表,以及一份将在全国妇女协会网站上发表的非专业版本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAULINE M MAKI其他文献
PAULINE M MAKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAULINE M MAKI', 18)}}的其他基金
EFFECTS OF MENOPAUSE TRANSITION ON BRAIN STRUCTURE, FUNCTION, AND COGNITION
更年期过渡对大脑结构、功能和认知的影响
- 批准号:
10283070 - 财政年份:2021
- 资助金额:
$ 4.64万 - 项目类别:
EFFECTS OF MENOPAUSE TRANSITION ON BRAIN STRUCTURE, FUNCTION, AND COGNITION
更年期过渡对大脑结构、功能和认知的影响
- 批准号:
10673908 - 财政年份:2021
- 资助金额:
$ 4.64万 - 项目类别:
Neural mechanisms of HIV-associated CNS dysfunction despite viral suppression
尽管病毒受到抑制,HIV相关中枢神经系统功能障碍的神经机制
- 批准号:
10217992 - 财政年份:2019
- 资助金额:
$ 4.64万 - 项目类别:
Neural mechanisms of HIV-associated CNS dysfunction despite viral suppression
尽管病毒受到抑制,HIV相关中枢神经系统功能障碍的神经机制
- 批准号:
9983174 - 财政年份:2019
- 资助金额:
$ 4.64万 - 项目类别:
Neural mechanisms of HIV-associated CNS dysfunction despite viral suppression
尽管病毒受到抑制,HIV相关中枢神经系统功能障碍的神经机制
- 批准号:
10412029 - 财政年份:2019
- 资助金额:
$ 4.64万 - 项目类别:
Menopausal Vasomotor Symptoms and Brain Aging in Women
女性更年期血管舒缩症状和大脑老化
- 批准号:
9927134 - 财政年份:2016
- 资助金额:
$ 4.64万 - 项目类别:
Menopausal Vasomotor Symptoms and Brain Aging in Women
女性更年期血管舒缩症状和大脑老化
- 批准号:
10654010 - 财政年份:2016
- 资助金额:
$ 4.64万 - 项目类别:
Menopausal Vasomotor Symptoms and Brain Aging in Women
女性更年期血管舒缩症状和大脑老化
- 批准号:
9148629 - 财政年份:2016
- 资助金额:
$ 4.64万 - 项目类别:
Effects of Estradiol & Phytoestrogens on Stress Responsivity
雌二醇的作用
- 批准号:
8072596 - 财政年份:2009
- 资助金额:
$ 4.64万 - 项目类别:
Effects of Estradiol & Phytoestrogens on Stress Responsivity
雌二醇的作用
- 批准号:
8274899 - 财政年份:2009
- 资助金额:
$ 4.64万 - 项目类别:
相似海外基金
Indicators of Accelerated Aging in Asian American Childhood Survivors
亚裔美国童年幸存者加速衰老的指标
- 批准号:
10910604 - 财政年份:2023
- 资助金额:
$ 4.64万 - 项目类别:
Longitudinal Examination of Neighborhood Disadvantage, Cognitive Aging, and Alzheimer's Disease Risk in Disinvested, African American Neighborhoods
对投资撤资的非裔美国人社区的社区劣势、认知老化和阿尔茨海默病风险进行纵向调查
- 批准号:
10370185 - 财政年份:2022
- 资助金额:
$ 4.64万 - 项目类别:
50th Annual Meeting of the American Aging Association
美国老龄化协会第 50 届年会
- 批准号:
10468570 - 财政年份:2022
- 资助金额:
$ 4.64万 - 项目类别:
The Black American United Memory & Aging Project (BA-UMAP): An examination of cognitive decline in midlife and older Black adults using remote cognitive assessments, risk factors & biomarkers
美国黑人联合记忆
- 批准号:
10686987 - 财政年份:2022
- 资助金额:
$ 4.64万 - 项目类别:
Longitudinal Examination of Neighborhood Disadvantage, Cognitive Aging, and Alzheimer's Disease Risk in Disinvested, African American Neighborhoods
对投资撤资的非裔美国人社区的社区劣势、认知老化和阿尔茨海默病风险进行纵向调查
- 批准号:
10565869 - 财政年份:2022
- 资助金额:
$ 4.64万 - 项目类别:
The Black American United Memory & Aging Project (BA-UMAP): An examination of cognitive decline in midlife and older Black adults using remote cognitive assessments, risk factors & biomarkers
美国黑人联合记忆
- 批准号:
10526152 - 财政年份:2022
- 资助金额:
$ 4.64万 - 项目类别:
51st Annual Meeting of the American Aging Association
美国老龄化协会第 51 届年会
- 批准号:
10602831 - 财政年份:2022
- 资助金额:
$ 4.64万 - 项目类别:
Advancing Native American Diversity in Aging Research through Undergraduate Education (Native American ADAR)
通过本科教育促进美国原住民老龄化研究的多样性(美国原住民 ADAR)
- 批准号:
10460942 - 财政年份:2021
- 资助金额:
$ 4.64万 - 项目类别:
Advancing Native American Diversity in Aging Research through Undergraduate Education (Native American ADAR)
通过本科教育促进美国原住民老龄化研究的多样性(美国原住民 ADAR)
- 批准号:
10172529 - 财政年份:2021
- 资助金额:
$ 4.64万 - 项目类别:
Diversity Supplement to Psychosocial Stress due to COVID-19 and Vascular Aging in African-American Women
对非裔美国女性因 COVID-19 和血管老化造成的心理社会压力进行多样性补充
- 批准号:
10709289 - 财政年份:2021
- 资助金额:
$ 4.64万 - 项目类别:














{{item.name}}会员




